GNH USA

Europe — EMA

Metformina + Sitagliptina Grindeks (Metformin Hydrochloride, Sitagliptin)

GNH USA supplies Metformina + Sitagliptina (Metformin hydrochloride and sitagliptin), a biguanide/DPP‑4 inhibitor for type 2 diabetes mellitus.

Metformin Hydrochloride, Sitagliptin

Request sourcing

1
Pack/s

What is Metformin Hydrochloride, Sitagliptin?

Metformin hydrochloride and sitagliptin, the active ingredients in Metformina + Sitagliptina Grindeks, constitute a biguanide and DPP‑4 inhibitor presented as a fixed‑dose oral tablet for oral use. The combination is indicated for the management of type 2 diabetes mellitus in adult patients when diet, exercise, and monotherapy are insufficient.

GNH USA supplies Metformina + Sitagliptina Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable delivery across multiple continents through a robust logistics network.

What is Metformin Hydrochloride, Sitagliptin used for?

Metformina + Sitagliptina Grindeks is used in the management of type 2 diabetes mellitus, targeting hyperglycemia through complementary mechanisms.

- Type 2 diabetes mellitus: improves overall glycemic control when diet, exercise, and monotherapy are insufficient. - Adjunct to metformin therapy: provides additional glucose‑lowering effect for patients inadequately controlled on metformin alone. - Combination therapy with other antidiabetics: enables dual action alongside sulfonylureas, insulin or GLP‑1 agonists to achieve target HbA1c.

What are the side effects of Metformin Hydrochloride, Sitagliptin?

The combination may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Mild hypoglycemia: especially when used with sulfonylureas or insulin. - Upper respiratory tract infection: transient symptoms.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal metabolic complication. - Acute pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic failure: signs of liver dysfunction. - Severe hypoglycemia: prolonged loss of consciousness or seizures.

What precautions apply to Metformin Hydrochloride, Sitagliptin?

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Renal function: assess eGFR and avoid use in severe renal impairment. - Hepatic disease: use with caution; monitor liver enzymes. - Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia. - Pregnancy and lactation: discuss potential risks with the prescriber. - Drug interactions: review concomitant medications for additive hypoglycemic risk. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

What does Metformin Hydrochloride, Sitagliptin interact with?

Metformina + Sitagliptina may interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - Severe renal impairment: contraindicates metformin component. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may increase metformin exposure. - Concurrent use of another DPP‑4 inhibitor: duplicate pharmacologic effect.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: heightened risk of hypoglycemia. - Loop diuretics: may affect renal clearance of metformin. - Iodinated contrast agents: temporary discontinuation of metformin recommended. - Alcohol excess: increases lactic acidosis risk. - Beta‑blockers: may mask hypoglycemia symptoms.

Frequently asked questions

What is Metformina + Sitagliptina used for?+
Metformina + Sitagliptina is prescribed for the treatment of type 2 diabetes mellitus in adults. It combines two mechanisms—decreasing hepatic glucose output and enhancing incretin activity—to improve overall blood‑sugar control when diet, exercise, or single‑agent therapy are insufficient.
How does metformin hydrochloride work in this combination?+
Metformin hydrochloride lowers blood glucose primarily by inhibiting hepatic gluconeogenesis and increasing peripheral insulin sensitivity. This reduces the amount of glucose released into the bloodstream and improves the uptake of glucose by muscle and fat tissues, contributing to better glycemic control.
What is the usual dose of Metformina + Sitagliptina?+
The specific dose and dosing schedule are determined by the prescribing healthcare professional based on individual patient factors such as renal function, current glycemic control, and concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.
Is Metformina + Sitagliptina safe during pregnancy or breastfeeding?+
Safety in pregnancy and lactation has not been fully established. The prescriber should evaluate the potential benefits against possible risks before initiating therapy in pregnant or nursing women, and alternative treatments may be considered when appropriate.
How do I order Metformina + Sitagliptina from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does this combination compare with other antidiabetic options?+
Compared with metformin monotherapy, the addition of sitagliptin offers a complementary DPP‑4 inhibition pathway, often resulting in greater HbA1c reduction. Unlike sulfonylureas, it carries a lower intrinsic risk of hypoglycemia, and unlike insulin, it is administered orally without injection.
What are the recommended storage conditions for Metformina + Sitagliptina?+
Store the tablets at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.
How is Metformina + Sitagliptina administered?+
The medication is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed.
What are the most serious risks associated with this medication?+
The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, and acute pancreatitis related to sitagliptin. Patients should be aware of symptoms such as severe abdominal pain, unexplained fatigue, rapid breathing, or muscle pain and seek immediate medical attention if they occur.
Who should not use Metformina + Sitagliptina?+
Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, or a history of lactic acidosis should avoid this medication. It is also contraindicated in individuals with certain hepatic conditions or in those taking other DPP‑4 inhibitors.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Metformin Hydrochloride, Sitagliptin
Route
Oral Use
Manufacturer
Grindeks
Origin
EU

Related products

Adiabin

Adiabin

Metformin Hydrochloride, Sitagliptin

Pharmextracta S.P.A
EU
Ansifora Duo

Ansifora Duo

Metformin Hydrochloride, Sitagliptin

Vipharm S.A.
EU
Ansifora Duo

Ansifora Duo

Metformin Hydrochloride, Sitagliptin

Vipharm S.A.
EU
Ansifora Duo

Ansifora Duo

Metformin Hydrochloride, Sitagliptin

Vipharm S.A.
EU